Demographic, clinical and laboratory variables of SLE cases and age- and gender-matched healthy controls
| Variable | SLE patients (n=27) | Controls (n=22) | p Value |
|---|---|---|---|
| Age (years), mean (SD) | 41.5 (14.1) | 38.5 (9.3) | 0.56 |
| Female | 26 (96.3) | 19 (86.3) | 0.96 |
| Caucasian | 17(63.0) | 20 (91.0) | 0.20 |
| BP systolic (mm Hg) | 131 (103, 144) | 119 (114, 127) | 0.78 |
| BP diastolic (mm Hg) | 76 (66, 86) | 77 (69, 80) | 0.84 |
| AHT therapy | 12 (44.0) | 0 (0) | 0.002 |
| BMI (kg/m2) | 25.7 (21.5, 28.5) | 25.1 (23.1, 30.8) | 0.42 |
| WC (cm) | 80 (74, 91.6) | 80 (72, 93.5) | 0.86 |
| Total cholesterol (mmol/l) | 5.2 (4.6, 6.7) | 5.54 (4.83, 6.87) | 0.54 |
| HDL-cholesterol (mmol/l) | 1.33 (1.15, 1.61) | 1.66 (1.46, 1.78) | 0.06 |
| LDL-cholesterol (mmol/l) | 2.71 (1.92, 3.6) | 3.01 (2.70, 3.58) | 0.35 |
| Triglycerides (mmol/l) | 1.36 (0.90, 1.87) | 0.88 (0.64, 1.00) | 0.01 |
| Lipid-lowering therapy | 3 (11) | 0 (0) | 0.18 |
| Glucose (mmol/l) | 4.40 (4.1, 5.0) | 4.9 (4.8, 5.1) | 0.05 |
| Diabetes | 2 (7.4) | 0 (0) | 0.28 |
| Family history of CVD | 10 (43.5) | 4 (18.2) | 0.09 |
| MetS | 11 (40.7) | 1/15 (6.7) | 0.03 |
| Fasting insulin (mU/l) | 16.3 (12.4, 22.9) | 14.0 (12.2, 20.6) | 0.55 |
| HOMA2-IR | 2.3 (1.9, 3.0) | 2.0 (1.8, 2.9) | 0.50 |
| Adiponectin (mg/l) | 3.57 (2.46, 5.90) | 2.93 (2.42, 3.60) | 0.12 |
| hsCRP (mg/l) | 2.4 (0.5, 5.1) | 0.51 (0.26, 2.83) | 0.09 |
Unless otherwise stated, values are n (%) or median (IQR).
AHT, anti-hypertensive; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; HOMA2-IR, homoeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MetS, metabolic syndrome; SLE, systemic lupus erythematosus; WC, waist circumference.